Profund Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-2,911
| Closed | -$384K | – | 1048 |
|
|
2025
Q1 | $384K | Sell |
2,911
-1,818
| -38% | -$227K | 0.02% | 565 |
|
|
2024
Q4 | $395K | Sell |
4,729
-1,304
| -22% | -$107K | 0.01% | 631 |
|
|
2024
Q3 | $441K | Sell |
6,033
-645
| -10% | -$48.5K | 0.02% | 584 |
|
|
2024
Q2 | $457K | Sell |
6,678
-4,396
| -40% | -$305K | 0.02% | 528 |
|
|
2024
Q1 | $766K | Buy |
11,074
+127
| +1% | +$8.73K | 0.03% | 431 |
|
|
2023
Q4 | $784K | Sell |
10,947
-1,185
| -10% | -$68.2K | 0.03% | 383 |
|
|
2023
Q3 | $632K | Buy |
12,132
+1,135
| +10% | +$66.1K | 0.03% | 401 |
|
|
2023
Q2 | $696K | Sell |
10,997
-271
| -2% | -$16.9K | 0.04% | 410 |
|
|
2023
Q1 | $610K | Buy |
11,268
+3,065
| +37% | +$148K | 0.04% | 446 |
|
|
2022
Q4 | $434K | Buy |
8,203
+492
| +6% | +$24.7K | 0.03% | 463 |
|
|
2022
Q3 | $359K | Sell |
7,711
-13
| -0.2% | -$679 | 0.03% | 502 |
|
|
2022
Q2 | $441K | Buy |
7,724
+190
| +3% | +$10.8K | 0.03% | 471 |
|
|
2022
Q1 | $461K | Buy |
7,534
+494
| +7% | +$25.7K | 0.02% | 619 |
|
|
2021
Q4 | $368K | Buy |
7,040
+283
| +4% | +$11.9K | 0.01% | 827 |
|
|
2021
Q3 | $252K | Sell |
6,757
-564
| -8% | -$19.6K | 0.01% | 1084 |
|
|
2021
Q2 | $298K | Buy |
7,321
+642
| +10% | +$23.7K | 0.01% | 1072 |
|
|
2021
Q1 | $227K | Buy |
+6,679
| New | +$232K | 0.01% | 1186 |
|
|
2019
Q1 | – | Sell |
-12,084
| Closed | -$138K | – | 1248 |
|
|
2018
Q4 | $138K | Sell |
12,084
-2,795
| -19% | -$45.1K | 0.01% | 1072 |
|
|
2018
Q3 | $323K | Buy |
+14,879
| New | +$311K | 0.01% | 1146 |
|
Other funds holding ITCI
KIM
HNB
Profund Advisors's ITCI Position: Q2 2025 in Review
Profund Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 2,911 shares — an estimated $384K sold.
Profund Advisors first reported a position in ITCI in Q3 2018 and held it in 19 quarters. The position peaked at $784K in Q4 2023. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Profund Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Profund Advisors sold 2,911 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $384K.
- Profund Advisors first reported a position in Intra-Cellular Therapies Inc. in Q3 2018 and held it in 19 quarters.
- Profund Advisors's Intra-Cellular Therapies Inc. position peaked at $784K in Q4 2023.
- 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Profund Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.